Cargando…
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
BACKGROUND: Only one head-to-head comparison of advanced treatments in moderately to severely active ulcerative colitis (UC) has been published; therefore, there remains a need for further comparisons. AIM: The relative treatment effects of filgotinib and adalimumab, golimumab, infliximab, tofacitin...
Autores principales: | Lu, Xiaoyan, Jarrett, James, Sadler, Susannah, Tan, Min, Dennis, James, Jairath, Vipul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147762/ https://www.ncbi.nlm.nih.gov/pubmed/36484968 http://dx.doi.org/10.1007/s11096-022-01509-1 |
Ejemplares similares
-
Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2023) -
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023) -
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Kobayashi, Taku, et al.
Publicado: (2023) -
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021) -
Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)